Dispatches from Korea
Ambition
Construction on the $275m third plant is yet to begin, but the site’s plans to almost double capacity by 2021 mirror Celltrion’s own ambitious history. Meanwhile a robust biosimilar pipeline and three proprietary biological products demonstrate how far the company has come in 15 years.
Jeong Won Yun puts this down to an ambitious attitude, combined with “hard work” and knowledgeable staff.
“Our partners say to us: ‘You’ve been alive for 15 years and you’ve done so much.’ We continue to grow based on our ambition.”